REPLIGEN CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)
REPLIGEN CORP (RGEN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) of $103.12 thousand for the 6-month period ending 2014-06-30, per its 10-Q filed 2014-08-11.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease · last filed 2014-08-11
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2014-06-30 was $5.35K, a 84.89% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2014-03-31 was $97.78K.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2013-12-31 was $44.67K, a 88.76% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for the quarter ending 2013-09-30 was $65.11K, a 76.52% decline year-over-year.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2013 was $91.19K, a 87.62% decline from fiscal 2012.
- REPLIGEN CORP fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, period increase (decrease) for fiscal 2012 was $736.85K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2014-06-30 | $5.35K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $103.12K 10-Q · filed 2014-08-11 | $147.79K derived: sum of 3 quarters · filed 2014-08-11 | $212.90K derived: sum of 4 quarters · filed 2014-08-11 |
| 2014-03-31 | $97.78K 10-Q · filed 2014-05-09 | $142.45K derived: sum of 2 quarters · filed 2014-05-09 | $207.56K derived: sum of 3 quarters · filed 2014-05-09 | $242.94K derived: sum of 4 quarters · filed 2014-05-09 |
| 2013-12-31 | $44.67K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $109.78K derived: sum of 2 quarters · filed 2014-03-14 | $145.16K derived: sum of 3 quarters · filed 2014-03-14 | $91.19K 10-K · filed 2014-03-14 |
| 2013-09-30 | $65.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $100.50K derived: sum of 2 quarters · filed 2013-11-08 | $46.52K 10-Q · filed 2013-11-08 | $443.94K derived: sum of 4 quarters · filed 2013-11-08 |
| 2013-06-30 | $35.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | -$18.59K 10-Q · filed 2013-08-07 | $378.83K derived: sum of 3 quarters · filed 2013-08-07 | $656.13K derived: sum of 4 quarters · filed 2013-08-07 |
| 2013-03-31 | -$53.97K 10-Q · filed 2013-05-07 | $343.44K derived: sum of 2 quarters · filed 2013-05-07 | $620.74K derived: sum of 3 quarters · filed 2013-05-07 | |
| 2012-12-31 | $397.42K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $674.72K derived: sum of 2 quarters · filed 2013-03-15 | $736.85K 10-K · filed 2013-03-15 | |
| 2012-09-30 | $277.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $339.43K 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $62.13K 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |